Zurich Cantonal Bank
RAPP icon

Zurich Cantonal Bank’s Rapport Therapeutics RAPP Stock Holding History

Zurich Cantonal Bank’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$267K Sell
7,932
-6,324
-44% -$273K ﹤0.01% 2235
2026
Q2 		$594K Buy
14,256
+13,743
+2,679% +$505K ﹤0.01% 1850
2026
Q1 		$16.1K Buy
+513
New +$14.4K ﹤0.01% 2464

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $54.9B AUM 27.38% 1-Year Est. Return

Zurich Cantonal Bank's RAPP Position: Q3 2026 in Review

Zurich Cantonal Bank reduced its Rapport Therapeutics (RAPP) stake by 44% in Q3 2026, selling an estimated $273K and leaving 7,932 shares worth $267K. The position accounts for ﹤0.01% of the portfolio, ranked #2235.

Zurich Cantonal Bank first reported a position in RAPP in Q1 2026 and has held it in 3 quarters since. The position peaked at $594K in Q2 2026. 114 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Zurich Cantonal Bank held 7,932 shares of Rapport Therapeutics worth $267K as of Q3 2026.
  • Zurich Cantonal Bank sold 6,324 Rapport Therapeutics shares in Q3 2026, an estimated $273K.
  • Rapport Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q3 2026, its #2235 holding.
  • Zurich Cantonal Bank first reported a position in Rapport Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Zurich Cantonal Bank's Rapport Therapeutics position peaked at $594K in Q2 2026.
  • 114 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Zurich Cantonal Bank's 13F filing for Q3 2026, filed 10 Nov 2026.